297 related articles for article (PubMed ID: 22586301)
21. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
23. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
24. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
[TBL] [Abstract][Full Text] [Related]
26. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Wilson C; Nicholes K; Bustos D; Lin E; Song Q; Stephan JP; Kirkpatrick DS; Settleman J
Oncotarget; 2014 Sep; 5(17):7328-41. PubMed ID: 25193862
[TBL] [Abstract][Full Text] [Related]
27. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
29. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Liang W; Kujawski M; Wu J; Lu J; Herrmann A; Loera S; Yen Y; Lee F; Yu H; Wen W; Jove R
Clin Cancer Res; 2010 Feb; 16(3):924-35. PubMed ID: 20103658
[TBL] [Abstract][Full Text] [Related]
31. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
[TBL] [Abstract][Full Text] [Related]
34. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
36. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
37. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
38. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
39. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
[TBL] [Abstract][Full Text] [Related]
40. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]